Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, multinational, multi-center, prospective, open-label study to asses effectiveness, safety and tolerability of treatment with vildagliptin or vildagliptin plus metformin (SPC) in type 2 diabetes mellitus patients in a real-world setting - GUARD

Next Previous
Trial Profile

An observational, multinational, multi-center, prospective, open-label study to asses effectiveness, safety and tolerability of treatment with vildagliptin or vildagliptin plus metformin (SPC) in type 2 diabetes mellitus patients in a real-world setting - GUARD

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary) ; Vildagliptin/metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GUARD
  • Sponsors Novartis Healthcare

    • Most Recent Events

    • 01 May 2017 Results (n=2786) assessing the effectiveness, safety, and tolerability of vildagliptin treatment with or without metformin in the patient subset from Egypt, published in the Current Medical Research and Opinion.
    • 30 Dec 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top